Roche H1 FY26 IFRS operating profit drops 6% to CHF 9.7 billion; sales fall 2% to CHF 30.4 billion

  • Roche first-half sales fell 2% to CHF 30.36 billion as the Swiss franc’s appreciation weighed on reported results.
  • IFRS operating profit dropped 6% to CHF 9.67 billion, while core operating profit edged down 1% to CHF 11.86 billion.
  • Core diluted EPS slipped 2% to CHF 10.85; IFRS diluted EPS declined 8% on currency effects.
  • Pharmaceuticals sales eased 1% to CHF 23.63 billion; Diagnostics sales declined 3% to CHF 6.74 billion.
  • Roche confirmed its 2026 outlook for mid-single-digit sales growth at constant exchange rates and high-single-digit core EPS growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230100OMX_____CNEWS_EN_GNW1001214047_en) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.